Cargando…

Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma

BACKGROUND: The Liver Imaging Reporting and Data System (LI-RADS) and European Association for the Study of the Liver (EASL) criteria are widely used for diagnosing hepatocellular carcinoma (HCC). Radiomics allows further quantitative tumor heterogeneity profiling. This study aimed to compare the di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Hanyu, Liu, Xijiao, Chen, Jie, Wei, Yi, Lee, Jeong Min, Cao, Likun, Wu, Yuanan, Duan, Ting, Li, Xin, Ma, Ling, Song, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896342/ https://www.ncbi.nlm.nih.gov/pubmed/31806050 http://dx.doi.org/10.1186/s40644-019-0266-9

Ejemplares similares

MRI-Based Radiomics Models to Discriminate Hepatocellular Carcinoma and Non-Hepatocellular Carcinoma in LR-M According to LI-RADS Version 2018
por: Zhang, Haiping, et al.
Publicado: (2022)

Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC
por: Erkan, Burcu, et al.
Publicado: (2019)

CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma
por: Lv, Kun, et al.
Publicado: (2021)

LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma
por: Yoon, Jongjin, et al.
Publicado: (2021)

Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation
por: Zhang, Yun, et al.
Publicado: (2020)

Differentiation of small (≤ 3 cm) hepatocellular carcinomas from benign nodules in cirrhotic liver: the added additive value of MRI-based radiomics analysis to LI-RADS version 2018 algorithm
por: Zhong, Xi, et al.
Publicado: (2021)

Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection
por: Shao, Shuo, et al.
Publicado: (2020)

Modified EASL-CLIF criteria that is easier to use and perform better to prognosticate acute-on-chronic liver failure
por: Thuluvath, Paul J, et al.
Publicado: (2022)

CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors
por: Huang, Zhe, et al.
Publicado: (2023)

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

The value of the apparent diffusion coefficient value in the Liver Imaging Reporting and Data System (LI-RADS) version 2018
por: Saleh, Gehad Ahmad, et al.
Publicado: (2022)

Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI
por: Liu, Xinai, et al.
Publicado: (2022)

Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging
por: Lee, Sunyoung, et al.
Publicado: (2020)

Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization
por: Bartnik, Krzysztof, et al.
Publicado: (2021)

A nomogram model integrating LI-RADS features and radiomics based on contrast-enhanced magnetic resonance imaging for predicting microvascular invasion in hepatocellular carcinoma falling the Milan criteria
por: Liu, Hai-Feng, et al.
Publicado: (2022)

Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018
por: Lee, Sang Min, et al.
Publicado: (2021)

Machine Learning-Based CEMRI Radiomics Integrating LI-RADS Features Achieves Optimal Evaluation of Hepatocellular Carcinoma Differentiation
por: Liu, Hai-Feng, et al.
Publicado: (2023)

Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS
por: Hu, Yi-Xin, et al.
Publicado: (2021)

CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017—Can Things Be Put Together?
por: Caraiani, Cosmin, et al.
Publicado: (2021)

JHEP Reports: A new EASL open access journal
por: Zucman-Rossi, Jessica
Publicado: (2019)

Diagnostic Performance of LI-RADS v2018 versus KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging with Hepatobiliary Agent: A Systematic Review and Meta-Analysis of Comparative Studies
por: Shin, Jaeseung, et al.
Publicado: (2023)

LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid–enhanced MRI for early recurrence risk stratification after curative resection
por: Wei, Hong, et al.
Publicado: (2020)

MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma
por: Zhou, Changwu, et al.
Publicado: (2021)

Thriving in turbulent times: EASL reflects on 2021, looking to 2022 and beyond
por: Berg, Thomas, et al.
Publicado: (2022)

Texture analysis on gadoxetic acid enhanced-MRI for predicting Ki-67 status in hepatocellular carcinoma: A prospective study
por: Ye, Zheng, et al.
Publicado: (2019)

Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma
por: Moura Cunha, Guilherme, et al.
Publicado: (2021)

Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS
por: Cannella, Roberto, et al.
Publicado: (2021)

Modified CEUS LI-RADS using Sonazoid for the diagnosis of hepatocellular carcinoma
por: Sugimoto, Katsutoshi, et al.
Publicado: (2023)

Diagnostic Value of CEUS LI-RADS Version 2017 in Differentiating AFP-Negative Hepatocellular Carcinoma from Other Primary Malignancies of the Liver
por: Wang, Peihua, et al.
Publicado: (2021)

Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey
por: Kondili, Loreta A., et al.
Publicado: (2022)

Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid
por: Sugimoto, Katsutoshi, et al.
Publicado: (2020)

Major and Ancillary Features According to LI-RADS in the Assessment of Combined Hepatocellular-cholangiocarcinoma
por: Granata, Vincenza, et al.
Publicado: (2020)

Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review
por: Voizard, Nicolas, et al.
Publicado: (2019)

Compared with CT/MRI LI-RADS, whether CEUS LI-RADS is worth popularizing in diagnosis of hepatocellular carcinoma?—a direct head-to-head meta-analysis
por: Wang, Hong, et al.
Publicado: (2023)

Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)
por: Brennan, Paul N, et al.
Publicado: (2021)

Hepatocellular carcinoma: radiomics nomogram on gadoxetic acid-enhanced MR imaging for early postoperative recurrence prediction
por: Zhang, Zhen, et al.
Publicado: (2019)

Ultrasound Radiomics Nomogram to Diagnose Sub-Centimeter Thyroid Nodules Based on ACR TI-RADS
por: Lu, Wenwu, et al.
Publicado: (2022)

Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm
por: An, Chansik, et al.
Publicado: (2016)

EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
Publicado: (2016)

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper
por: Boettler, Tobias, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pmee63i923ac2k6hf8vlt48nma